Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients.
Détails
ID Serval
serval:BIB_0E0E478D9B11
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients.
Périodique
Alimentary Pharmacology and Therapeutics
Collaborateur⸱rice⸱s
Swiss IBD Cohort Study Group
Contributeur⸱rice⸱s
Bauerfeind P., Beglinger C., Begré S., Bengoa J., Binek J., Boller D., Borovicka J., Braegger C., Burnand B., Camara R., Criblez D., de Saussure P., Degen L., Delarive J., Ehmann T., Engelmann M., Wafa AE., Felley C., Frei A., Frei P., Frei R., Fried M., Froehlich F., Gallot-Lavallée S., Gerlach T., Geyer M., Girardin M., Goetze O., Haack H., Hediger S., Hengstler P., Heyland K., Janiak P., Juillerat P., Brondolo VK., Knoblauch C., Kullak-Ublick GA., Maillard M., Manser C., Marbet U., Manz M., Meier R., Meyenberger C., Michetti P., Mottet C., Müller C., Müllhaupt B., Nicolet T., Nydegger A., Piccoli F., Pilz J., Pittet V., Rentsch R., Rey JP., Rogler D., Rogler G., Sagmeister M., Sauter B., Schaub N., Schibli S., Schoepfer AM., Seibold F., Spalinger J., Stadler P., Steuerwald M., Straumann A., Sulz M., Thorens£££Joël£££ J. , Vader JP., Vavricka SR., Vögtlin J., Von Känel R., Wachter G., Wermuth J., Wiesel P.
ISSN
1365-2036 (Electronic)
ISSN-L
0269-2813
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
42
Numéro
5
Pages
540-548
Langue
anglais
Notes
Publication types: Journal ArticlePublication Status: ppublish
Résumé
BACKGROUND: Studies that systematically assess change in ulcerative colitis (UC) extent over time in adult patients are scarce.
AIM: To assess changes in disease extent over time and to evaluate clinical parameters associated with this change.
METHODS: Data from the Swiss IBD cohort study were analysed. We used logistic regression modelling to identify factors associated with a change in disease extent.
RESULTS: A total of 918 UC patients (45.3% females) were included. At diagnosis, UC patients presented with the following disease extent: proctitis [199 patients (21.7%)], left-sided colitis [338 patients (36.8%)] and extensive colitis/pancolitis [381 (41.5%)]. During a median disease duration of 9 [4-16] years, progression and regression was documented in 145 patients (15.8%) and 149 patients (16.2%) respectively. In addition, 624 patients (68.0%) had a stable disease extent. The following factors were identified to be associated with disease progression: treatment with systemic glucocorticoids [odds ratio (OR) 1.704, P = 0.025] and calcineurin inhibitors (OR: 2.716, P = 0.005). No specific factors were found to be associated with disease regression.
CONCLUSIONS: Over a median disease duration of 9 [4-16] years, about two-thirds of UC patients maintained the initial disease extent; the remaining one-third had experienced either progression or regression of the disease extent.
AIM: To assess changes in disease extent over time and to evaluate clinical parameters associated with this change.
METHODS: Data from the Swiss IBD cohort study were analysed. We used logistic regression modelling to identify factors associated with a change in disease extent.
RESULTS: A total of 918 UC patients (45.3% females) were included. At diagnosis, UC patients presented with the following disease extent: proctitis [199 patients (21.7%)], left-sided colitis [338 patients (36.8%)] and extensive colitis/pancolitis [381 (41.5%)]. During a median disease duration of 9 [4-16] years, progression and regression was documented in 145 patients (15.8%) and 149 patients (16.2%) respectively. In addition, 624 patients (68.0%) had a stable disease extent. The following factors were identified to be associated with disease progression: treatment with systemic glucocorticoids [odds ratio (OR) 1.704, P = 0.025] and calcineurin inhibitors (OR: 2.716, P = 0.005). No specific factors were found to be associated with disease regression.
CONCLUSIONS: Over a median disease duration of 9 [4-16] years, about two-thirds of UC patients maintained the initial disease extent; the remaining one-third had experienced either progression or regression of the disease extent.
Pubmed
Web of science
Open Access
Oui
Création de la notice
28/07/2015 14:49
Dernière modification de la notice
20/08/2019 12:35
Données d'usage
